*Department of Cardiology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark;

†Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark;

‡Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark;

§Department of Cardiology, Zealand University Hospital, Roskilde, Denmark;

¶Department of Cardiology, Copenhagen University Hospital, Copenhagen, Denmark;

‖Department of Cardiology, Royal North Shore Hospital and University of Sydney, St Leonards, NSW, Australia; and

**Department of Emergency Medicine, Copenhagen University Hospital Herlev-Gentofte, Herlev, Denmark.

Correspondence: Hashmat Sayed Zohori Bahrami, MD, Department of Cardiology, Copenhagen University Hospital Hvidovre, Kettegård Alle 30, 2650 Hvidovre, Denmark (e mail: [email protected]).

Supported by The Heart Centre Research Foundation, Rigshospitalet; The A.P. Møller and Chastine Mc-Kinney Møller Foundation; and The Novo Nordic Foundation. The sponsors did not influence the study's design or the collection, analysis or interpretation of data, the writing of the manuscript, or the decision to submit the manuscript for publication.

H. Bundgaard and H. Rasmussen are named inventors on a patent owned by Royal North Shore Hospital and the University of Sydney for the use of ?3-AR agonists to treat heart failure. The remaining authors report no conflicts of interest.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jcvp.org).